Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $36.1 million.

  • Century Therapeutics' Operating Expenses rose 152.89% to $36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year decrease of 4.55%. This contributed to the annual value of $144.7 million for FY2024, which is 272.55% down from last year.
  • Latest data reveals that Century Therapeutics reported Operating Expenses of $36.1 million as of Q3 2025, which was up 152.89% from $34.7 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Operating Expenses registered a high of $44.0 million during Q4 2023, and its lowest value of $32.2 million during Q1 2024.
  • In the last 4 years, Century Therapeutics' Operating Expenses had a median value of $35.2 million in 2023 and averaged $35.9 million.
  • Within the past 5 years, the most significant YoY rise in Century Therapeutics' Operating Expenses was 3016.23% (2023), while the steepest drop was 1219.15% (2023).
  • Over the past 4 years, Century Therapeutics' Operating Expenses (Quarter) stood at $33.8 million in 2022, then surged by 30.16% to $44.0 million in 2023, then fell by 5.84% to $41.5 million in 2024, then fell by 12.86% to $36.1 million in 2025.
  • Its last three reported values are $36.1 million in Q3 2025, $34.7 million for Q2 2025, and $35.0 million during Q1 2025.